8-K

                United States Securities and Exchange Commission
                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

                        Date of Report: February 2, 2007

              (Date of earliest event reported: February 1, 2007)

                               ONCOLOGIX TECH INC.
             (Exact name of registrant as specified in its charter)

          Nevada                   001-15482                    86-1006416
 ---------------------------       ----------                 -----------------
(State or other jurisdiction      (Commission                (IRS Employer
      of incorporation)           File Number)               Identification No.)

                      2850 Thornhills Ave., S.E., Suite 104
                             Grand Rapids, Michigan               49546
                     --------------------------------------      --------
                    (Address of principal executive offices)    (Zip Code)

                                 (616) 977-9933
                          -----------------------------
                         (Registrant's telephone number)


Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:

[ ]  Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act
     (17 CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))




Item 8.01  Other Events

On January 31, 2007 the registrant published a Press Release describing the
accomplishment of the first "milestone" in the development of its Oncosphere
product. Pursuant to the terms of its Merger Agreement with JDA Medical
Technologies, Inc. the attainment of that milestone fulfilled the condition for
the release from escrow of 7,460,792 shares of the Registrant's common stock to
the four holders thereof, who were principal shareholders of JDA, among whom the
following individuals are currently officers or directors of the Registrant:
Andrew Green, Andrew S. Kennedy, MD, and Adam Lowe.

Item 9.01 Financial Statements and Exhibits

(a)  Exhibits
     --------

Exhibit             Title

99                  Press release issued by Oncologix Tech Inc. dated
                    February 1, 2007




                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                            BestNet Communications Corporation

                                            By:  /s/  Stanley L. Schloz
                                               --------------------------------
                                                      Stanley L. Schloz
                                                      President

                                            By:  /s/  Michael A. Kramarz
                                               --------------------------------
                                                      Michael A. Kramarz
                                                      Chief Financial Officer


Date: February 2, 2007

EX-99

                                                                      Exhibit 99


   ONCOLOGIX TECH INC. (FORMERLY BESTNET COMMUNICATIONS CORP.) ACHIEVES FIRST
                          MAJOR DEVELOPMENT MILESTONE

GRAND RAPIDS, Mich.--(PR Newswire) -- February 1, 2007 - Oncologix Tech Inc.'s
(formerly BestNet Communication Corp.) (OTC BB: BESC) wholly owned subsidiary
Oncologix Corporation announced today an early completion of the first of three
performance milestones, the Development Phase, for its Oncosphere product. The
Company also stated that because of the change in its name, it expects a new
symbol for the trading of its securities on the OTC Bulletin Board in the near
future.

In completing the Development Phase Oncologix successfully manufactured
microspheres that are representative of the microspheres that will be used for
the next phase, Pre-Clinical Testing. Additionally, the manufactured product
demonstrates that the design and manufacturing process are reproducible in
scalable quantities at reasonable costs. The end of this phase was scheduled for
July 2007 and its completion allows Oncologix to enter the next project phase
for the Oncosphere System earlier than originally anticipated.

Completion of each of three performance milestones, as defined by the July 26,
2006 merger agreement with JDA Medical Technologies Inc., allows the release of
escrowed shares of Oncologix common stock to the former principal shareholders
of JDA. Completion of the development phase permits a total of 7,460,792 shares
of stock to be released from the escrow. The shareholders may sell the shares
under the provisions of SEC Rule 144.

According to Andrew Green, CEO of Oncologix, "We are extremely pleased to
announce the successful completion of the Development Phase and are excited by
the progress that our team has made with the Oncosphere project. We now have a
product that we are confident in testing to support a request to the FDA to
start a clinical trial. I believe that with these results we can expect to be
treating patients in early 2008."

Andrew S. Kennedy, MD, Chief Science and Medical Officer of Oncologix, stated,
"I am delighted that we have produced a design for our microsphere treatment,
and I am most excited about beginning animal studies to verify the product's
safety and performance. I am looking forward to initiating human studies in the
near future using our Oncosphere product."

About Oncologix Tech Inc. and Oncologix Corp.:

Oncologix  Tech Inc.,  (formerly  BestNet  Communications  Corp.) was formerly a
provider of long distance telephone communication services. During January 2007,
the Company entered into an agreement to dispose of the telephone business.

Oncologix Corporation, based in Atlanta GA, is a wholly owned subsidiary of
Oncologix Tech Inc.. Oncologix is developing advanced medical treatments for
soft tissue cancers; the Oncosphere System. The Oncosphere System is a
brachytherapy (radiation therapy) device being developed for the treatment of
soft tissue cancers. It is based on a radioactive micro-particle designed to
deliver therapeutic radiation directly to a tumor site by introducing the
micro-particles into the artery that feeds the tumor tissue.

This release contains forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended, which are intended to be
covered by the "safe harbor" created thereby. These statements include the plans
and objectives of management for future operations, including plans and
objectives. The forward-looking statements herein are based on current
expectations that involve judgments with respect to, among other things, future
economic, competitive and market conditions and future business decisions, all
of which are difficult or impossible to predict accurately and many of which are
beyond control of the company. Although the company believes that the
assumptions underlying the forward-looking statements are reasonable, any one of
the assumptions could be inaccurate and, therefore, can be no assurance that the
forward-looking statements included in this release will prove to be accurate.